Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TWST.
← Back to Free Index

TWST

Analysis as of: 2026-02-20
Twist Bioscience Corporation
Twist Bioscience manufactures synthetic DNA products (genes, oligo pools, libraries) and adjacent NGS workflow and protein/antibody solutions via direct sales and e-commerce ordering.
automation biotech hardware healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

DNA writing scales as AI accelerates biology
The core bet is that AI increases experiment volume and pushes scarcity into high-quality DNA manufacturing. If margins hold above 50% and breakeven arrives on plan, a tools-peer rerating supports 2–3× equity upside into 2031.

Analysis

Thesis
AI makes biological design cheap, shifting value to reliable “DNA writing” capacity, speed, and compliance; if Twist sustains >50% gross margin, embeds into enterprise ordering workflows, and monetizes trust/audit tiers, it can grow into a durable mid-cap life-science tools compounder by 2031.
Last Economy Alignment
Twist controls a scarce physical bottleneck (high-throughput synthetic DNA manufacturing) that benefits as AI increases experiment velocity; main obsolescence risk is price compression from incumbents/new synthesis modalities.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.7x (from 5 most recent analyses)
Reasoning
Twist’s upside is mostly a de-risking + share-gain story: rising AI-enabled discovery increases order volume and construct complexity, while profitability improves if automation lifts gross margin and operating leverage. The big non-linear option is workflow embedding (agent/API ordering + manufacturing-coupled “rules” checks + paid audit tiers) that raises reorder stability and willingness to pay for speed/quality, even if per-base pricing drifts down over time.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is value-capture: synthesis pricing can compress as competitors add capacity or new modalities mature, while Twist also faces a real single-supplier dependency that can disrupt throughput. The company’s near-term equity narrative is tightly gated by (i) sustaining >50% gross margin while scaling qualified output and (ii) hitting the 4QFY26 adjusted EBITDA breakeven target to reduce dilution risk; a miss would likely force slower growth or new financing.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They own a high-throughput DNA “factory” that benefits as AI makes designing experiments easier and faster, pushing more orders into manufacturing bottlenecks. The threat is that better-funded incumbents or new synthesis methods turn DNA into a commodity and squeeze pricing before Twist’s scale flywheel fully compounds.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$49.89
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case